Bacuyong, Juanito, Jr. S.

HRN: 21-95-36  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/11/2022
CEFTAZIDIME 1GM (VIAL)
10/11/2022
10/18/2022
IV
2g
Q12h
Ruptured Viscus
Waiting Final Action 
10/11/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/11/2022
10/18/2022
IV
500mg
Q8h
Ruptured Viscus
Waiting Final Action 
10/14/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/14/2022
11/03/2022
IV
4.5g
Q6
Intraabdominal Infection
Waiting Final Action 
10/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/20/2022
10/27/2022
IV
500mg
Q8
Intra-abdominal Infection
Waiting Final Action 
10/20/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/20/2022
10/28/2022
IV
2.25gms
Q6
Empirical Escalation
Waiting Final Action 
10/29/2022
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
10/29/2022
11/04/2022
IV
750mg
OD
Septicemia
Waiting Final Action 
10/29/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/29/2022
11/04/2022
IV
4.5gm
Q6
Septicemia, HAP
Waiting Final Action 
11/02/2022
LEVOFLOXACIN 500MG (TAB)
11/02/2022
11/09/2022
PO
500mg
OD
Septicemia; Intra Abdominal Infection
Waiting Final Action 
11/05/2022
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
11/05/2022
11/12/2022
TOPICAL
1%
TID
Decubitus Ulcer
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: